| NIM | G1A016105 |
|---|
| Namamhs | DELIMA ROCHMAH NUR SYAHBANI |
|---|
| Judul Artikel | Perbedaan Kadar Hemoglobin Sebelum dan Sesudah Kemoterapi (Cisplatin-Paclitaxel) pada Pasien Kanker Nasofaring di RSUD Prof. Dr.Margono Soekarjo |
|---|
| Abstrak (Bhs. Indonesia) | Latar Belakang: Terapi kanker nasofaring berdasarkan National Comprehensive Cancer Network merekomendasikan induction chemotheraphy + concurrent chemoradiotheraphy sebagai salah satu perawatan standar untuk penyakit kanker nasofaring stadium II-IVA. Penggunaan induction chemotheraphy diberikan sebelum radioterapi, menjadi strategi pengobatan yang efektif karena memiliki tingkat kepatuhan yang lebih baik dan memfasilitasi pemberantasan dini mikrometastasis. Namun, kemoterapi memiliki efek samping supresi sumsum tulang dan mengurangi hormon eritropoietin di ginjal. Penurunan kadar hemoglobin dapat memperburuk defisiensi oksigen pada tumor sehingga meningkatkan sel-sel hipoksia dan berkontribusi terhadap perkembangan resistensi radioterapi. Tujuan: Mengetahui kadar hemoglobin sebelum dan sesudah kemoterapi (cisplatin-paclitaxel) pada pasien kanker nasofaring. Desain Penelitian: Penelitian analitik observasional yang menggunakan pendekatan cross sectional. Subjek penelitian sebanyak 36 pasien kanker nasofaring yang menjalani 6 siklus kemoterapi dan memenuhi kriteria penelitian. Hasil: Hasil analisis bivariat menggunakan Paired T Test didapatkan perbedaan rerata kadar hemoglobin sebelum dan sesudah kemoterapi (p=0,000), rerata kadar hemoglobin sebelum kemoterapi yakni 13,39 g/dL dan sesudah kemoterapi yakni 11,35 g/dL pada pasien kanker nasofaring di RSUD Prof. Dr. Margono Soekarjo. Kesimpulan: Terdapat perbedaan signifikan antara kadar hemoglobin sebelum dan sesudah kemoterapi (cisplatin-paclitaxel) pada pasien kanker nasofaring di RSUD Prof. Dr. Margono Soekarjo. |
|---|
| Abtrak (Bhs. Inggris) | Background: Nasopharyngeal cancer therapy based on the National Comprehensive Cancer Network recommends induction chemotheraphy +concurrent chemoradiotheraphy as one of the standard treatments for stage II-IVA nasopharyngeal cancer. The use of induction chemotheraphy given before radiotherapy, is an effective treatment strategy because it has a better level of adherence and facilitates early eradication of micrometastasis. Chemotherapy has a direct side effect of disruption of erythrocyte formation in the bone marrow and reduces the erythropoietin hormone in the kidney. Decreased hemoglobin levels exacerbate oxygen deficiency in tumors thereby increasing hypoxic cells and contributing to the development of radiotherapy resistance. Objective: This research was conducted to find out the hemoglobin levels before and after chemotheraphy (cisplatin-paclitaxel) in nasopharyngeal cancer patients. Design: An analytical observational studies with cross sectional method. The subjects were 36 nasopharyngeal cancer patients that gone through 6 cycles of chemotherapy and meets the research criteria. Result: The results of the bivariate analysis showed differences in the average hemoglobin levels before and after chemotherapy, the average hemoglobin levels before chemotherapy which were 13.39 g/dL and after chemotherapy which were 11.35 g/dL in nasopharyngeal cancer patients at Prof. Hospital Dr. Margono Soekarjo (p = 0,000). Consclusions: There is a significant difference between hemoglobin levels before and after chemotherapy (cisplatin-paclitaxel) in nasopharyngeal cancer patients in Prof. Dr. Margono Soekarjo Hospital. |
|---|
| Kata kunci | Hemoglobin, Kemoterapi, Kanker Nasofaring |
|---|
| Pembimbing 1 | dr. Sekti Joko Suntono Islamanto, Sp. THT-KL |
|---|
| Pembimbing 2 | dr.Vitasari Indriani, M.M., M.Si.Med, Sp.PK |
|---|
| Pembimbing 3 | |
|---|
| Tahun | 2016 |
|---|
| Jumlah Halaman | 82 |
|---|
| Tgl. Entri | 2020-05-21 07:49:45.541647 |
|---|